Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feedback is welcome. This article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.
On July 14, Golden Age Health Pte. Ltd. (GAH) and Innostellar Biotherapeutics announced the signing of aLasting for ten yearsThe exclusive "Promotion Service Agreement." According to the agreement, GAH will obtain the exclusive rights to commercially promote Innostellar Biotherapeutics' first-in-class (BIC) gene therapy candidate drug LX101 in mainland China.LX101 is an adeno-associated virus (AAV) gene therapy designed to deliver a functional RPE65 gene to retinal cells in order to restore the visual cycle in patients with biallelic RPE65 mutation-associated inherited retinal dystrophy (IRD).Currently under Phase III clinical trial development in China,Key data is expected to be released in the fourth quarter of 2025.And plans to actively submit a New Drug Application (NDA) to the China National Medical Products Administration (NMPA). If approved, LX101 will offer an eligible patient population a single-dose, long-lasting treatment option aimed at halting or potentially reversing vision loss.GAH will leverage its comprehensive patient service platform covering disease and medical education, market access, and patient support to address unmet needs along the patient journey, such as disease awareness, timely diagnosis and treatment, and treatment accessibility and affordability. Through close collaboration, the two parties will swiftly bring this life-changing therapy to patients in China affected by hereditary retinal dystrophy caused by RPE65 gene mutations, enabling them to "see a clearer future."。Inherited Retinal Dystrophies (IRDs) – including Retinitis Pigmentosa (RP) – are a group of genetic disorders that progressively damage photoreceptor cells, leading to severe vision loss or blindness, typically starting in childhood. The prevalence of RP worldwide is approximately 1/3000–1/4000 and it has been officially included in China's First List of Rare Diseases (2018), indicating the attention given to patients suffering from these conditions.Reference: Company Announcement
